Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01818063

An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer

Study identifier: NCT01818063
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Triple-negative breast cancer
  • no prior treatment for breast cancer
  • Clinical stage IIB, IIIA, IIIB, or IIIC

Type of study:

Phase II

Treatment:

Participants will be assigned to one of two groups

  • 21-days cycles where participants receive paclitaxel and carboplatin intravenously on day 1 or 2
  • 21-days cycles where participants receive paclitaxel and carboplatin intravenously on day 3 or 4 AND veliparib orally on days 1-5

Study site:

Pennsylvania
Philadelphia
Thomas Jefferson University
Contact: Tiffany Avery, MD, MPH 215-955-1661
Contact: Clinical Research Management Office 215-955-1661

 

Page updated 06/10/13